• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • Contact
    • About

Governments Spent at Least €93bn on COVID-19 Vaccines and Therapeutics During the Last 11 Months

January 11, 2021 By Press Release Distribution Network Leave a Comment

According to analysis conducted by kENUP Foundation, the public sector has dedicated at least €93bn to COVID-19 vaccines and therapeutics in 2020. More than 95%, about €88.3bn, was spent on vaccine companies. Only 5% of public COVID-19 funds were spent on therapeutics.

Highlights
New figures from kENUP Foundation show extent of public investments in COVID-19 vaccines and therapeutics
95% of funds in support of vaccines, with just 5% allocated to therapeutics
Most funding was granted through a novel mechanism: 93% of all public funds were committed through advance market commitments (AMC), e.g. by Operation Warp Speed in the United States, or by the European Commission
Geographically, 32% of public funds came from the United States, 24% from the EU and its Member States, and 13% from Japan and South Korea
On the vaccine side, 71% of public funding went into products under development by SMEs and MidCaps, with only 18% deployed to large pharmaceutical manufacturers

Most of the funds, around €86.5bn, were used to conclude advance market commitments (AMCs). In return for the right to buy a specified number of vaccine doses in a given timeframe, governments finance part of the upfront costs faced by vaccines producers in the form of AMCs. Just 7% of funds were spent through preferred loans or conventional grants.

The data also shows the origin of the funding: 32% of funds directed towards vaccine producers come from the US, 24% from the EU, and a total of 13% from the governments of Japan and South Korea.

For vaccines, exceptionally, governments invested 71% or at least €63.1bn into Small and Medium Enterprises (SMEs) and MidCaps. Only 18% of funds went to big pharma, underlining the importance of SMEs in driving innovation.

Holm Keller, Chairman of kENUP Foundation said: “Public investments have been instrumental in supporting innovation in the fight against the coronavirus. To bridge the time until broad rollout of vaccines, further investment in therapeutics is especially important. In parallel, a dedicated public pandemic preparedness scheme that would make vaccines and therapeutics readily available at lower development costs for any kind of pandemic pathogen is needed”.

The figures are kENUP’s analysis of publicly available information. They do not include private sector investments. The data was correct as at January 10, 2021.

About kENUP Foundation:

kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in health industries for societal benefit. kENUP initiates public and private investment into innovations with the potential to improve the livelihood of every citizen. The development of such innovations is often hampered by failing markets. Through its work, kENUP aims to change that.

Related

Filed Under: Press Release

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • insightsoftware’s Embedded Analytics Solutions Named A Leader in 2022 Business Intelligence Market Study by Dresner Advisory Services
  • ESG Book Closes $35 million Series B to Build the World’s Leading ESG Data Platform
  • OpenAP Introduces new OpenAP Data Hub to Power the Future of Television Advertising with Snowflake
  • PUBLIC SERVICES INTERNATIONAL LAUNCHES INTERACTIVE DOCUMENTARY EXPERIENCE ON GLOBAL HEALTH WORKERS
  • Media Intelligence Digest
  • Coding Digest
  • Microsoft Names Cloudflare the Winner of its Security Software Innovator Of The Year Award
  • Globalstar Announces Successful Launch of Spare Satellite
  • Tipper Gore donates $1 Million to Razom for Ukraine
  • Mkt Dev 2022

Media Partners

  • Opinion
  • Exclusive
  • Briefly
  • OPINT
  • VPNW
  • S3H
  • Domain Aftermarkets
  • App Coding
  • API Coding
  • Blockchaining

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Domain Market Research
  • Pixel Effect

Copyright © 2019 PressMediaRelease.com

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT